Back To Search Instructions
Protocols
18 protocols meet the specified criteria
Disease Site: Lung
Protocol No.TitleStatus
1403269898Clinical study of the effect of combined treatment of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers Open
1508065953Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (A151216) (A Screening Trial for A081105 and E4512)Open
1509119432E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
1509137444Randomized Double Blind Placebo Controlled Study of Erlotinib orObservation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR)Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST) (A081105)Open
1602381312A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSNot Open
1604536433A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose- Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1607720505EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersOpen
1701157446METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1703270664A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic MelanomaOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
1706540415Real-Time Optical Biopsy for Improved Lung Cancer DiagnosisOpen
1709868869Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB-1158) as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid TumorsOpen
1802269227A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid TumorsOpen
PHXB-15-0011-80-15SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerOpen
PHXB-17-0013-71-16Dosimetric comparison for IMRT, VMAT, SBRT/SRS, & Brachytherapy for extracranial sitesOpen
PHXE-17-0216-10-15EAY131: Molecular Analysis for Therapy Choice (MATCH) Open
PHXE-17-0349-10-15DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsOpen